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HIV-2 Infection and HIV-1/HIV-2
Dual Reactivity in Patients With
and Without AIDS-Related
Symptoms in Gabon
To the Editor: Between 1996 and 1997, we
evaluated the incidence of HIV-2 infection at the
Fondation Jeanne Ebori, the second largest
hospital in Libreville, capital of Gabon; we found
an unexpected high prevalence of HIV-2–infected
or HIV-1/HIV-2–dually reactive patients.
During a 10-month period, 147 (14.3%) of
1,029 sera from inpatients and outpatients were
found HIV-positive by the type III method
recommended by the World Health Organization
(two  enzyme-linked immunosorbent assays are
used to screen anti-HIV antibodies) (1). Further
discrimination between HIV-1 and HIV-2
infections was assessed by using synthetic
peptides specific for the gp41 and the gp120 of
HIV-1 and the gp36 of HIV-2 (ImmunoComb II,
PBS Orgenics, Illkirch, France). Of the 147 HIV-
positive sera, 141 (96.0%) were exclusively HIV-
1–positive; four were exclusively HIV-2–positive;
and two were both HIV-1– and HIV-2–positive.
Of the six sera with anti-gp36/HIV-2 reactivities,
two (from patients A and B) were positive on HIV-
2 Western blot, with marked anti-gag HIV-1
cross-reactivity and a discrimination assay
positive only for HIV-2; two (from patients D and
E) were positive on HIV-2 Western blot, with
anti-gag and pol reactivities markedly lower than
anti-env reactivities and a discrimination assay
positive only for HIV-2; the two remaining sera
(from patients C and F) showed typical dual
reactivities for HIV-1 and HIV-2 infections, with
positive patterns of HIV-1 and HIV-2 Western
blots and a discrimination test positive for both
viruses. As a whole, six (4.1%) of 147 HIV-positive
sera showed either HIV-2 infection alone (n = 4)
or dual reactivity. Of those, four were from
Gabonese patients B, C, D, and E, and two were
from immigrants from West Africa (patient A
from Mali and patient F from Nigeria); two were
female patients B and E. Among Gabonese
patients, only one (patient E) had traveled to
West Africa; the remaining three had never
visited any neighboring country. However, one
Gabonese man (patient C) lived in Port-Gentil,
which has many West African immigrants. For
all patients, the most likely risk factor for HIV
was a heterosexual relationship with an
unknown HIV-infected person. In three asymp-
tomatic patients (A, B, and C) the HIV-2–
serostatus was unexpected; in contrast, the three
other patients had AIDS-related symptoms.
Patients D and E had an HIV-2 Western blot
pattern showing a marked decrease in anti-gag
and pol reactivities compatible with their
advanced stage of HIV-2 disease.
The case of a 55-year-old exclusively
heterosexual asymptomatic woman (patient B)
suggests the possibility of a specific variant of
HIV-2 in Central Africa (2). The high frequency in
primates in Gabon of natural infection with simian
immunodeficiency retroviruses, which show a
high degree of genetic relatedness to HIV-2 (3),
could support such a hypothesis.
Two patients had typical dual reactivities to
HIV-1 and HIV-2 antigens. To our knowledge,
such dual reactivities have never been reported
in Gabon (4). In the patient from Nigeria (patient
F), the serologic pattern was typical of that
usually observed in West Africa (5). Dual
reactivity can result from genuine mixed
infections and from serologic cross-reactivity in
HIV-1 and HIV-2 infection alone; theoretically, it
could also represent infection with a different,
cross-reacting recombinant strain (5).
HIV-2 infection in Gabon is epidemiologically
related to West Africa, because of cultural and,
above all, economic ties. However, HIV-2 is not
limited to immigrant populations from West
Africa or to Gabonese citizens traveling in this
area; it has also reached the indigenous Gabonese131 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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population. The possibility of rare cases of HIV-1
and HIV-2 coinfections, recombinant HIV-1 and
HIV-2 strains, and also peculiar HIV-2 variants
from Central Africa, should be considered in
Gabon. A possible entry of HIV-2 infection into
Central Africa from Gabon in the near future
could have major public health implications.
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Q Fever in French Guiana: New Trends
To the Editor: Q fever, the endemic disease
caused by the rickettsial organism Coxiella
burnetii, was first described in French Guiana in
1955 (1). Only sporadic cases were reported until
1996 when three patients were hospitalized in
the intensive care unit of the Cayenne Hospital
for acute respiratory distress syndrome. One of
the patients died. Many cases of Q fever were
diagnosed in the general population at the same
time. A seroepidemiologic study was performed
to determine whether the increase in cases was
due to an increase in incidence or to an
improvement in diagnosis. All paired samples of
sera (acute-phase and convalescent-phase) from
patients sent to the arbovirus laboratory for
diagnosis of dengue infection from January 1,
1992, to December 31, 1996, were tested for
antibodies to C. burnetii by immunofluorescence.
All positive samples were also tested for
immunoglobulin (IgM) by the same method; the
IgG and IgM titers were determined by using a
serial twofold dilution. A diagnosis of Q fever
was made when there was a seroconversion
from negative to positive or a twofold increase
in IgG titer associated with the presence of IgM
in the second sample.
One hundred and fifty-one of 426 paired sera
collected between 1992 and 1996 were from
patients recently infected with dengue fever.
Twenty-five (9.1%) of 275 remaining sera were from
Q fever patients. Significant differences were
observed in the rates of Q fever in different years (p
< 0.01); one (1.9%) of 53 was positive in 1992, five
(9.1%) of 55 in 1993, five (8.6%) of 58 in 1994, three
(4.8%) of 63 in 1995; a large increase was observed
in 1996 (11 [23.9%] of 46). Differences by residence
were also assessed. Rates of infection were higher in
Cayenne (21 [13.0%] of 161) than in rural areas (4
[3.5%] of 114) (p < 0.01).
This study shows that cases of Q fever have
occurred in French Guiana in recent years and
that a significant increase in the incidence rate
occurred in 1996. The reasons for this increase
are unclear, and further studies of the
epidemiology of Q fever in French Guiana are
necessary. The epidemiology of Q fever is unusual
in French Guiana because the rates of infection
are much higher in Cayenne, the capital city,
than in rural areas. No link with classical sources
of infection (cattle, sheep, or goat birth products,
or work in a slaughterhouse) was found. Indeed,
Cayenne, with 80,000 inhabitants, is located near
the Atlantic Ocean, and the prevailing winds
blow from the sea. Airborne contamination from
rural areas is therefore impossible. Furthermore,
no large farm is in the immediate vicinity of the
city. For identical reasons, contamination from
the abattoirs is not likely; they are located on
the west side of the city, near the Cayenne
River, and the winds blow from the east. In our
study, cases were almost equally distributed